The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHOC 2022 | The impact of reduced intensity conditioning for allogeneic SCT in AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the impact of reduced intensity conditioning for allogeneic stem cell transplantation (alloSCT) in acute myeloid leukemia (AML). Prof. Nagler first explains the high toxicity associated with previous forms of myeloablative conditioning, and then goes on to comment on how reduced intensity conditioning has improved the efficacy and safety of transplantation over the years. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
